1. Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinase
   Zhuo Yu et al, 2018, Sci Rep CrossRef
2. Total Flavones of Abelmoschus manihot Exhibits Pro-Angiogenic Activity by Activating the VEGF-A/VEGFR2-PI3K/Akt Signalling Axis
   Gui-Song Zhu et al, 2018, Am. J. Chin. Med. CrossRef
3. New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin
   Chien-shan Cheng et al, 2019, Cancer Cell Int CrossRef
4. Apoptotic Pathway as the Therapeutic Target for Anticancer Traditional Chinese Medicines
   Weixiao An et al, 2019, Front. Pharmacol. CrossRef
5. Jolkinolide A and Jolkinolide B Inhibit Proliferation of A549 Cells and Activity of Human Umbilical Vein Endothelial Cells
   Lei Shen et al, 2017, Med Sci Monit CrossRef
6. Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo
   Jiann-Hwa Chen et al, 2019, Cancers CrossRef
7. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells
   Li Wang et al, 2020, Biomedicine & Pharmacotherapy CrossRef
8. The coffee diterpene kahweol enhances sensitivity to sorafenib in human renal carcinoma Caki cells through down-regulation of Mcl-1 and c-FLIP expression
   Kyoung-Jin Min et al, 2017, Oncotarget CrossRef
9. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling
   Haiyong Wang et al, 2018, Int J Oncol CrossRef
10. Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins
    Haiyong Wang et al, 2018, Mol Med Report CrossRef
11. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status
    Sae Ishihara et al, 2019, Int J Oncol CrossRef
12. Molecular mechanisms of bufadienolides and their novel strategies for cancer treatment
    Li-Juan Deng et al, 2020, European Journal of Pharmacology CrossRef
13. Inhibitory effects of Paris saponin I, II, Ⅵ and Ⅶ on HUVEC cells through regulation of VEGFR2, PI3K/AKT/mTOR, Src/eNOS, PLCγ/ERK/MERK, and JAK2-STAT3 pathways
    Wenping Wang et al, 2020, Biomedicine & Pharmacotherapy CrossRef
14. Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway-related proteins.
    Marium M Shamaa, 2021, FEBS Open Bio CrossRef
15. Toad venom: A comprehensive review of chemical constituents, anticancer activities, and mechanisms.
    Fang-Jie Li et al, 2021, Arch Pharm (Weinheim) CrossRef
16. Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signalling pathway
    Kai Fang et al, 2021, J Transl Med CrossRef
17. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding
    Rao Fu et al, 2021, International Immunopharmacology CrossRef
18. 19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway
    Wei Yu et al, 2021, Exp Hematol Oncol CrossRef
19. Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology
    Jianbo Zhou et al, 2022, Front. Pharmacol. CrossRef
20. Bufalin for an innovative therapeutic approach against cancer
    Laura Soumoy et al, 2022, Pharmacological Research CrossRef
21. Global trends in bufalin application research for cancer from 2003 to 2022: A bibliometric and visualised analysis
    Tang Donghao et al, 2024, Heliyon CrossRef